Patients treated with immunosuppressive steroids are less aware of sick day rules Than those on endocrine replacement therapy and may be at greater risk of adrenal crisis.

BACKGROUND: Patients taking corticosteroids for immune suppression are vulnerable to adrenal crisis during acute illness or if steroids are stopped abruptly. Although patients treated for adrenal failure in endocrine units are routinely provided with sick day guidelines, we wished to ascertain whether patients on immunosuppressive steroids are appropriately advised. AIM: This study sets out to compare patient awareness of steroid sick day rules in endocrine and non-endocrine patients. DESIGN: A short case history is presented to illustrate the clinical impact of adrenal crisis in a patient on immune suppression. Subsequently, we present the results of a 9-point questionnaire, devised to determine knowledge of steroid sick day rules, in two patient cohorts. In group 1, patients on immunosuppressive steroids were recruited from non-endocrine clinics to complete the questionnaire. In group 2, patients on replacement steroids were recruited from endocrine clinics. RESULTS: Endocrine patients exhibited better steroid use awareness; they were more likely to double their steroid dose when ill (89 v/s 23%), to obtain parenteral steroid during vomiting (83 v/s 27%), or during surgery (87 v/s 30%), and were aware of the need to carry a MedicAlert bracelet or a steroid-aware card (82 v/s 21%), (p < 0.001 for all comparisons). CONCLUSION: Endocrine patients exhibited a significantly greater knowledge of sick day rules. The data does highlight the lack of patient awareness of the precautions for steroid use in patients on immunosuppressive steroid therapy for non-endocrine conditions, and the case presentation illustrates the potential hazards of this lack of awareness.

Abnormal plasma sodium concentrations in patients treated with desmopressin for cranial diabetes insipidus: results of a long-term retrospective study.

CONTEXT AND OBJECTIVE: Patients with cranial diabetes insipidus (CDI) are at risk of developing both hypernatraemia and hyponatraemia, due to the condition itself or secondary to treatment with vasopressin-analogues or during administration of i.v. fluids. We aimed to assess the frequency and impact of dysnatraemias in the inpatient (INPT) and outpatient (OPT) setting in desmopressin-treated CDI, comparing those with normal thirst with those with abnormal thirst. DESIGN: The study included 192 patients with cranial diabetes, who were identified from the Beaumont Pituitary Database, a tertiary referral centre. Retrospective case note audit was performed and the clinical and biochemical information of 147 patients with CDI were available for analysis. RESULTS: A total of 4142 plasma sodium measurements for 137 patients with normal thirst, and 385 plasma sodium measurements for ten patients with abnormal thirst were analysed. In those with normal thirst, the most common OPT abnormality was mild hyponatraemia (pNa(+) 131-134  mmol/l) in 27%, while 14.6% had more significant hyponatraemia (pNa(+) ≤130  mmol/l). Of those patients with normal thirst, 5.8% were admitted due to complications directly related to hyponatraemia. Compared with patients with normal thirst, those with abnormal thirst were more likely to develop significant OPT hypernatraemia (20% vs 1.4%, P=0.02) and significant INPT hyponatraemia (50% vs 11.1%, P 0.02). CONCLUSION: OPT management of CDI is complicated by a significant incidence of hyponatraemia. In contrast, OPT hypernatraemia is almost exclusively a complication seen in adipsic CDI, who also had more frequent INPT hyponatraemia. CDI associated with thirst disorder requires increased physician attention and patient awareness of potential complications.